Michael Bates named VP of oncology R&D at Cepheid; IntegenX appoints Dennis Harris as CSO; Timothy Triche joins WaferGen Biosystems' board of directors; Diffinity Genomics appoints John Foskett and Robert Evans to board.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.